MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Geron Corporation - Common Stock (NQ:GERN)

1.580 -0.020 (-1.25%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Geron Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
News headline image
Geron to Participate at Upcoming Investor Conferences in March 2025
From Geron Corporation
Via Business Wire
News headline image
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
News headline image
4 Analysts Assess Geron: What You Need To Know ↗
 
Via Benzinga
News headline image
Geron to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
From Geron Corporation
Via Business Wire
News headline image
Analyst Scoreboard: 4 Ratings For Geron ↗
 
Via Benzinga
News headline image
Analyst Ratings For Geron ↗
 
Via Benzinga
News headline image
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
News headline image
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
News headline image
Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS
From Geron Corporation
Via Business Wire
News headline image
Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies
From Geron Corporation
Via Business Wire
News headline image
Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis
From Geron Corporation
Via Business Wire
News headline image
Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference
From Geron Corporation
Via Business Wire
News headline image
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
News headline image
Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development
From Geron Corporation
Via Business Wire
News headline image
Geron to Participate in the Stifel 2024 Healthcare Conference
From Geron Corporation
Via Business Wire
News headline image
Geron (GERN) Q3 2024 Earnings Call Transcript ↗
GERN earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors
From Geron Corporation
Via Business Wire
News headline image
Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Geron Corporation
Via Business Wire
News headline image
Geron Announces New Data to be Presented at Upcoming ASH Annual Meeting Highlighting the Potential of RYTELO™ (imetelstat) in Myeloid Hematologic Malignancies
From Geron Corporation
Via Business Wire
News headline image
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
News headline image
Geron to Announce Third Quarter 2024 Financial Results on November 7, 2024
From Geron Corporation
Via Business Wire
News headline image
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
News headline image
Geron Corporation Announces Appointment of Jim Ziegler as Chief Commercial Officer
From Geron Corporation
Via Business Wire
News headline image
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
News headline image
Geron (GERN) Q2 2024 Earnings Call Transcript ↗
GERN earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
GERN Stock Earnings: Geron Meets EPS, Beats Revenue for Q2 2024 ↗
GERN stock results show that Geron met analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Geron Corporation Reports Second Quarter 2024 Financial Results and Business Highlights
From Geron Corporation
Via Business Wire
News headline image
Geron Announces Updated NCCN Guidelines® Recommending RYTELO™ (imetelstat) for the Treatment of Symptomatic Anemia in Patients with Lower-Risk MDS
From Geron
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story